MHC
HAE icon

May Hill Capital’s Haemonetics HAE Stock Holding History

May Hill Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
22,388
+40
+0.2% +$2.57K 0.35% 56
2026
Q1 		$1.26M Hold
22,348
– – 0.32% 65
2025
Q4 		$1.79M Hold
22,348
– – 0.48% 41
2025
Q3 		$1.09M Buy
22,348
+4,431
+25% +$274K 0.32% 53
2025
Q2 		$1.34M Sell
17,917
-23
-0.1% -$1.52K 0.44% 44
2025
Q1 		$1.14M Buy
17,940
+25
+0.1% +$1.7K 0.43% 41
2024
Q4 		$1.4M Buy
+17,915
New +$1.44M 0.54% 31

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

May Hill Capital's HAE Position: Q2 2026 in Review

May Hill Capital increased its Haemonetics (HAE) stake by 0.18% in Q2 2026, buying an estimated $2.57K and bringing the position to 22,388 shares worth $1.68M. The position accounts for 0.35% of the portfolio, ranked #56.

May Hill Capital first reported a position in HAE in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.79M in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • May Hill Capital held 22,388 shares of Haemonetics worth $1.68M as of Q2 2026.
  • May Hill Capital bought 40 Haemonetics shares in Q2 2026, an estimated $2.57K.
  • Haemonetics made up 0.35% of May Hill Capital's portfolio in Q2 2026, its #56 holding.
  • May Hill Capital first reported a position in Haemonetics in Q4 2024 and has held it in 7 quarters since.
  • May Hill Capital's Haemonetics position peaked at $1.79M in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on May Hill Capital's 13F filing for Q2 2026, filed 7 Aug 2026.